Spero Therapeutics financials
$1.20+0.84%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.8M | $48.0M | $103.8M | $53.5M | $18.3M | $9.3M | $18.1M | $4.0M | $2.0M |
| Gross profit | $66.8M | $48.0M | $103.8M | $53.5M | $18.3M | $9.3M | $18.1M | $4.0M | $2.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $6.3M | -$73.4M | $26.8M | -$42.2M | -$88.0M | -$79.1M | -$63.2M | -$42.8M | -$41.7M |
| Net income | $8.6M | -$68.6M | $22.8M | -$46.4M | -$89.8M | -$78.8M | -$60.9M | -$41.7M | -$46.1M |
| Net margin | 12.8% | −142.9% | 22.0% | −86.7% | −491.7% | −844.9% | −335.7% | −1050.5% | −2329.3% |
| Diluted EPS | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 | $-3.52 | $-3.35 | $-2.60 | $-17.82 |
| EBITDA | $7.2M | -$72.5M | $27.2M | -$29.7M | -$87.3M | -$78.4M | -$62.5M | -$42.4M | -$41.4M |
| Operating cash flow | -$12.6M | -$23.4M | -$33.0M | -$6.8M | -$64.1M | -$85.9M | -$49.8M | -$39.6M | -$39.1M |
| Free cash flow | -$12.6M | -$23.4M | -$33.0M | -$6.8M | -$64.2M | -$86.0M | -$50.1M | -$42.1M | -$39.1M |
| Diluted shares | 59.0M | 54.0M | 53.0M | 37.6M | 30.9M | 22.4M | 18.2M | 16.0M | 2.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $40.3M | $52.9M | $76.3M | $109.1M | $112.6M | $85.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $33.8M | $41.7M |
| Total debt | $91.0K | $0.00 | $87.0K | $96.0K | $138.0K | $177.0K |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M | $153.5M |
| Total liabilities | $9.9M | $64.4M | $75.5M | $48.9M | $82.8M | $21.4M |
| Shareholders' equity | $59.0M | $46.1M | $106.9M | $75.9M | $88.3M | $132.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology